Publications by authors named "M Koroku"
Background: Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan.
Aim: To compare the real-world efficacy and safety of these three JAK inhibitors in UC.
Methods: This was a multicentre, retrospective study of patients with UC started on JAK inhibitors.
Introduction: Small bowel (SB) capsule endoscopy (SBCE) is a sensitive modality for screening the entire SB of patients with Crohn's disease (CD); however, the prognostic impact of the results is unclear. We evaluated the ability of the SBCE score to predict therapeutic intervention for patients with CD and SB lesions without clinical symptoms as well as negative C-reactive protein (CRP) levels.
Methods: Fifty-six patients who underwent a patency evaluation and had a CD activity index (CDAI) score <150 mg/dL and CRP level <0.
Background/aims: Small bowel capsule endoscopy (SBCE) is an evaluation method for small bowel (SB) lesions in Crohn's disease (CD). However, the relationship between SBCE findings and the serological biomarker leucine-rich alpha-2 glycoprotein (LRG) remains unclear. We aimed to establish appropriate cutoff values of LRG to predict the presence of SB lesions in CD through SBCE.
View Article and Find Full Text PDFArticle Synopsis
- Filgotinib, a JAK 1 inhibitor approved for ulcerative colitis (UC), has limited real-world data on its effectiveness and safety, prompting a multicenter study of patients using it from March 2022 to September 2023.
- The study found that among 238 UC patients, clinical remission rates increased from 47% at 10 weeks to 64.6% at 58 weeks, with a median follow-up of 28 weeks showing 39.9% achieving remission.
- Adverse events were low, with only 1.3% developing herpes zoster, indicating that filgotinib has promising efficacy and safety in the real-world setting for UC treatment.*
Article Synopsis
- This study evaluated a commercial AI-assisted colonoscopy system's effectiveness in assessing histological healing in patients with ulcerative colitis (UC) compared to traditional light endoscopy methods.
- The researchers analyzed data from 52 UC patients, focusing on the ability of both the Mayo endoscopic score (MES) and AI to predict histological healing, using the Geboes score as a standard.
- Results showed that the AI system's diagnostic performance was similar to that of the MES, indicating that AI could potentially reduce the need for histological examinations in evaluating healing.